Table 1.
Nano-forms of anti-cancer drugs
| Drug | Nano-drug | Target/action | Reference |
|---|---|---|---|
| Daunomycin | DaunoXome (liposome) | Leukaemia | (25) |
| Doxorubicin | Doxil/ Caelyx-encapsulation in PEGylated liposome Myocet-non-PEGylated liposome |
Acute leukaemia, lymphoma, breast carcinoma, osteosarcoma, haematological malignancies, Kaposi’s sarcoma Myocet-metastatic breast cancer in combination with cyclophosphamide |
(26) |
| Annamycin | Liposome | Leukaemia, reticulosarcoma | (26) |
| Tretinoin | Loaded nanocapsules; liposomes | Acute promyelitic leukaemia | (27) |
| Vincristine | Liposome | Chemotherapy-nephroblastoma, lymphoma, lymphoblastic leukaemia | (28) |
| Cisplatin | DMPG-complexed, entrapped in liposomes | Melanomas | (26) |
| Hydroxyrubicin (lipophilic prodrug) | Liposome | Leukaemia, reticulosarcoma | (26) |
| Mitoxantrone | Cytostatic complex with lipophilic acid | Metastatic breast cancer, acute myeloid leukaemia, non-Hodgkin’s lymphoma, acute lymphoblastic leukaemia | (26) |
| Paclitaxel/ Taxol | Lipophilic prodrug paclitaxel oleate in sterically stabilized | Lung, ovarian, and breast cancer | (29) |